The subsequent discovery of somatic alterations in the tyrosine kinase domain of the EGFR gene provided an explanation as to why only a fraction of lung cancer patients had excellent response to EGFR TKIs (Shigematsu and Gazdar, 2006; Suzuki et al., 2005). The gene discussed is EGFR; the disease is lung carcinoma.